Forecasting accurate revenue numbers was a critical

New Post Public Reply Private Reply Replies (5) Message Board
Mo
642

Forecasting accurate revenue numbers was a critical requirement in my career. We used self- explanatory categories of Best Case, Most Likely and Worse Case. My exercise in B-OM stand -alone value in post # 54930 used Worse Case numbers. The numbers I believe represent the Most Likely outcome for B-OM and IPIX in general are much higher. It is interesting that one poster tried to put a 22% success rate to knock my already low ball estimates by another 78%. First off the article he used for his stats is dated 2/14/11 which uses the previous 10 years data. A lot has changed in the last 8-18 years. The current Administration is also much more aggressive in getting new drugs to market than in the past. IPIX with B-OM as a simple swish-and-spit has a much better likelihood than "average" of a successful Phase 3. There is no drug available for the PREVENTION of OM. That gives the FDA even greater motivation for approval of B-OM. Even if you accept these outdated numbers we are still at 55% x 80 percent = 44 percent. The poster incorrectly divides again by half because that is the amount that get approved on the first attempt. That is a meaningless stat if shareholders are willing to wait for approval which we have proven with our patience. Using the outdated 44 percentage which again does not represent reality, we still come up with a B-OM ONLY share price of $4.25 to $8.50 or $15.05 to $30.10 depending on whether you use IONS PE of 41 or the biotech average of 145. With a huge IBD market we can probably multiply those #s by a minimum of 3x to 4x. Now we are at $12.75 to $25.50 on the LOW END of the estimate using the lower PE. We still haven't factored in dermatitis revenue to the Brilacidin franchise value. Note that once approved we are back to a minimum of 100% of my Low-ball estimate and not 44%. I would be OK with a Brilacidin franchise value with a STARTING POINT of $20+/share plus dermatitis in 2020 with great growth opportunity each additional year. Add in Kevetrin and we are easily looking at a $100 plus share price. Note that the majority of biotech companies do not have net earnings but many of those are still priced above $100/share. The minute a license deal is signed IPIX share dilution stops and IPIX becomes a rarity in the biotech field as it becomes profitable and will no longer be considered Pre-revenue. There is a premium added to companies that make money and still have huge upside growth potential.

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Compass Unveiled: Power Revolution in Private Equity

Updated Category News Views 5

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
HTX's Strategic Moves in Pakistan: A Crypto Frontier

Updated Category News Views 5

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 8

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
AI-Driven Lumi Transforms Car Dealership Interactions

Updated Category News Views 7

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 3

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 2

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading

Top 5 Most Recently Viewed Articles

In-Silico Clinical Trials Expected to Surge to $6.39 Billion

Updated Category News Views 196

In-Silico Clinical Trials Market Overview The in-silico clinical trials market is witnessing substantial growth, projected to reach USD 6.39 billion in the near future. This transformation reflects a significant shift in how pharmaceutical and medical technology companies approach drug development and clinical evaluation. By leveraging advanced digital technologies,...

Continue Reading
Longeveron Inc. Announces Significant Leadership Changes

Updated Category News Views 162

Longeveron Inc. Leadership Evolution Longeveron Inc. has recently made pivotal updates to its leadership team, signaling significant strategic shifts within the company. Than Powell is stepping up as the Interim CEO, while Dr. Joshua Hare, a cornerstone of the company, takes on the role of Executive Chairman of the Board. These changes come as the company aims to enhance...

Continue Reading
Aebi Schmidt Group's Growth Strategy Post-Merger Unveiled

Updated Category News Views 218

Aebi Schmidt Group's Strategic Vision After Merger Aebi Schmidt Group is actively trading under the ticker symbol "AEBI" after completing an exciting merger with The Shyft Group. The organization is well-positioned with a robust balance sheet, focusing on executing its post-merger strategies effectively. Amidst a dynamic operating environment, the company's commitment to...

Continue Reading
Unibail-Rodamco-Westfield Achieves Top ‘A’ Rating in Sustainability

Updated Category News Views 373

Unibail-Rodamco-Westfield's Commitment to Sustainability Unibail-Rodamco-Westfield, often abbreviated as URW, has accomplished an impressive feat by receiving a top ‘A’ rating from CDP for the seventh consecutive year. This recognition is a testament to the company's continuous efforts and transparent actions in combating climate change, all structured under its...

Continue Reading
Genstar Capital Hires Industry Veteran John Kufner for Advisory

Updated Category News Views 280

Big Moves in Private Equity: Genstar's New Addition What’s the deal here? Genstar Capital, that powerhouse in private equity, just scored big by bringing John Kufner on board as part of their Strategic Advisory Board. This isn’t just another hire; it's a strategic chess move. Kufner isn’t your run-of-the-mill executive—he's been around the block more than a few...

Continue Reading